Sanofi's Praluent Closes Gap On Repatha In Europe in latest CHMP opinions
This article was originally published in Scrip
Executive Summary
Sanofi/ Regeneron's PCSK9 inhibitor Praluent (alirocumab) is quickly catching its likely competitor, receiving a positive opinion from Europe's top scientific advisory body, the Committee for Medicinal Products for Human Use, only two months after another PCSK9 inhibitor, Amgen's Repatha (evolocumab) was recommended for approval by the European Medicines Agency panel.